日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

A Significant Decline of Glomerular Filtration Rate in the Majority of Long-Term Lithium Users: Results of a Dutch Prospective 10-Year Cohort Study

长期服用锂剂的患者中,大多数患者的肾小球滤过率显著下降:一项荷兰前瞻性10年队列研究的结果

van der Aa, M J; Zittema, D; Doornebal, J; Hartong, E G T M; Bisseling, E M; Dammers, J; Klumpers, U M H; Kerckhoffs, A P M; Kupka, R W; Nijenhuis, T

Use of the Urine-to-Plasma Urea Ratio to Predict ADPKD Progression

利用尿液与血浆尿素比值预测ADPKD进展

Heida, Judith E; Gansevoort, Ron T; Messchendorp, A Lianne; Meijer, Esther; Casteleijn, Niek F; Boertien, Wendy E; Zittema, Debbie

The Effect of Renal Function and Hemodialysis Treatment on Plasma Vasopressin and Copeptin Levels

肾功能和血液透析治疗对血浆血管加压素和血管加压素原水平的影响

Ettema, Esmée M; Heida, Judith; Casteleijn, Niek F; Boesten, Lianne; Westerhuis, Ralf; Gaillard, Carlo A J M; Gansevoort, Ron T; Franssen, Casper F M; Zittema, Debbie

Urine Concentrating Capacity, Vasopressin and Copeptin in ADPKD and IgA Nephropathy Patients with Renal Impairment

ADPKD和IgA肾病伴肾功能损害患者的尿浓缩能力、血管加压素和copeptin

Zittema, Debbie; Casteleijn, Niek F; Bakker, Stephan J L; Boesten, Lianne S M; Duit, A A Margreeth; Franssen, Casper F M; Gaillard, Carlo A J M; Gansevoort, Ron T

Dose-Titrated Vasopressin V2 Receptor Antagonist Improves Renoprotection in a Mouse Model for Autosomal Dominant Polycystic Kidney Disease

剂量滴定的血管加压素V2受体拮抗剂可改善常染色体显性多囊肾病小鼠模型的肾脏保护作用

Zittema, Debbie; Versteeg, Irina B; Gansevoort, Ron T; van Goor, Harry; de Heer, Emile; Veraar, Kimberley A M; Peters, Dorien J M; Meijer, Esther

Kidney function and plasma copeptin levels in healthy kidney donors and autosomal dominant polycystic kidney disease patients

健康肾脏捐献者和常染色体显性多囊肾病患者的肾功能和血浆血管加压素原水平

Zittema, Debbie; van den Berg, Else; Meijer, Esther; Boertien, Wendy E; Muller Kobold, Anneke C; Franssen, Casper F M; de Jong, Paul E; Bakker, Stephan J L; Navis, Gerjan; Gansevoort, Ron T